S
Susan H. Fox
Researcher at University of Toronto
Publications - 220
Citations - 17609
Susan H. Fox is an academic researcher from University of Toronto. The author has contributed to research in topics: Dyskinesia & Parkinson's disease. The author has an hindex of 56, co-authored 208 publications receiving 14500 citations. Previous affiliations of Susan H. Fox include University of Manchester & University Health Network.
Papers
More filters
Journal ArticleDOI
Update on current and emerging therapies for dystonia.
TL;DR: Oral anticholinergics, baclofen and clonazepam are used off-label, but novel drugs in development include sodium oxybate, zonisamide and perampanel and future gene-targeted therapies could benefit selected dystonia patients.
Journal ArticleDOI
The pill questionnaire in a nondemented Parkinson's disease population
William Reginold,William Reginold,Melissa J. Armstrong,Melissa J. Armstrong,Sarah Duff-Canning,Anthony E. Lang,Anthony E. Lang,David F. Tang-Wai,David F. Tang-Wai,Susan H. Fox,Susan H. Fox,Brandon Rothberg,Cindy Zadikoff,Nancy Kennedy,David J. Gill,Paul J. Eslinger,Mark Mapstone,Kelvin L. Chou,Carol Persad,Irene Litvan,Benjamin T. Mast,Connie Marras,Connie Marras +22 more
TL;DR: The Pill Questionnaire was assessed as a screen for mild cognitive impairment in nondemented Parkinson's disease patients and found it to be a good screening tool for the disease.
Journal ArticleDOI
Dopamine Reuptake Inhibitors in Parkinson’s Disease: A Review of Nonhuman Primate Studies and Clinical Trials
TL;DR: Alternative approaches to dopamine replacement in parkinsonism generally and to wearing-off and dyskinesia are urgently needed, and a hypothesis as to how tailoring the selectivity of DAT inhibitors might maximize the benefits of Dat inhibition in PD is proposed.
Journal ArticleDOI
Famotidine, a Histamine H2 Receptor Antagonist, Does Not Reduce Levodopa-Induced Dyskinesia in Parkinson's Disease: A Proof-of-Concept Study.
Tiago A. Mestre,Binit B. Shah,Barbara S. Connolly,Camila de Aquino,Amaal Al Dhakeel,Richard A. Walsh,Taneera Ghate,Jane P. Lui,Susan H. Fox +8 more
TL;DR: Famotidine seems to be safe in patients with PD and LID, but showed no potential as an antidyskinetic agent.
Journal ArticleDOI
DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.
Tom H. Johnston,Eboo Versi,Patrick A. Howson,Paula Ravenscroft,Susan H. Fox,Michael Hill,Bruce E. Reidenberg,Ronald Corey,Jonathan M. Brotchie +8 more
TL;DR: In parkinsonian 6‐OHDA lesioned rats and MPTP‐lesioned macaques, DPI‐289 provided anti‐parkinsonian actions as monotherapy and an enhancement of L‐DOPA benefit and has potential to improve the benefits of dopaminergic therapy in Parkinson's disease.